Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Subject must have had a diagnosis of primary or secondary warm antibody AIHA.~- Must have failed at least 1 prior treatment regimen for AIHA.~Exclusion Criteria:~* Subject with cold antibody AIHA, cold agglutinin syndrome, mixed type AIHA, or paroxysmal cold hemoglobinuria.~* Subject with a platelet count of \< 30,000/μL.~* Subject has AIHA secondary to autoimmune disease, including systemic lupus erythematosis (SLE), or lymphoid malignancy and the underlying disease is not stable or is not well-controlled on current therapy.~* Subject has uncontrolled or poorly controlled hypertension, defined as systolic blood pressure ≥ 130 mmHg, or diastolic blood pressure ≥ 80 mmHg.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fostamatinib 150 mg (Type: EXPERIMENTAL): Fostamatinib 150 mg bid (morning and evening) over the course of 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).